[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-365947-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-365947-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","cd320-receptor-and-vitamin-b12-as-potential-targets-for-anti-cancer-therapy","CD320 Receptor and Vitamin B12 as Potential Targets for Anti-Cancer Therapy","","Despite the development of numerous anticancer agents, many fail in patient treatment because untargeted cytotoxicity causes adverse effects. Selective therapies are needed to distinguish healthy from cancerous cells by focusing on proteins overexpressed in tumors. CD320, a receptor mediating cellular uptake of transcobalamin-bound vitamin B12 required for DNA synthesis and proliferation, is overexpressed in diverse cancers and may serve as an early biomarker. This review consolidates advances in CD320-targeted therapeutic strategies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cd320-receptor-and-vitamin-b12-as-potential-targets-for-anti-cancer-therapy/365947/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cd320-receptor-and-vitamin-b12-as-potential-targets-for-anti-cancer-therapy/365947.png","ImageObject",300,407,{"name":42,"@type":43},"นรินทร์","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is targeted therapy important for anticancer treatment?","Question",{"text":63,"@type":64},"Most anticancer agents are limited by adverse effects from untargeted cytotoxicity. Targeting cancer-specific proteins and pathways helps discriminate tumor from normal tissue.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What role does CD320 play in vitamin B12 uptake and cancer cell behavior?",{"text":68,"@type":64},"CD320 is responsible for cellular uptake of transcobalamin-bound vitamin B12 (cobalamin). This supports DNA synthesis and cell proliferation, and CD320 is overexpressed in many cancers.",{"name":70,"@type":61,"acceptedAnswer":71},"What therapeutic approaches involving CD320 are summarized in the review?",{"text":72,"@type":64},"The review summarizes advances including vitamin B12 therapeutic conjugates, CD320-specific antibodies and nanobodies, nanoparticle systems carrying cytotoxic drugs, and porphyrin-based strategies, as well as prospects for targeted therapy to attenuate tumor tissues.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},365947,1792196031,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336475104957,"https://ap-avatar.wpscdn.com/avatar/22000c4c6bd8a5076e1?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787554080175789136","Review  \nCD320 Receptor and Vitamin B12 as Potential Targets for Anti-Cancer Therapy  \nAinur Tolymbekova  and Larissa Lezina *  \nAcademic Editors: Rodolfo Ippoliti and Francesco Giansanti  \nReceived: 29 April 2025  \nRevised: 30 May 2025  \nAccepted: 1 June 2025  \nPublished: 12 June 2025  \nCitation: Tolymbekova, A.; Lezina, L. CD320 Receptor and Vitamin B12 as Potential Targets for Anti-Cancer Therapy. Int. J. Mol. Sci. 2025, 26, 5652 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms26125652  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \nSchool of Medicine, Nazarbayev University, Astana 010000, Kazakhstan; [ainur.tolymbekova@nu.edu.kz](ainur.tolymbekova@nu.edu.kz)  \n* Correspondence: [larisa.lezina@nu.edu.kz](larisa.lezina@nu.edu.kz); Tel.: +7-(717)-270-6570  \nAbstract: Despite the development of a wide plethora of different anticancer agents, most of them are not used for patient treatment due to adverse effects caused by untargeted cytotoxicity. To prevent this unwanted toxicity, it is necessary to develop therapies discriminating between healthy and cancerous cells. One possible method is to target proteins overexpressed in cancer but not in normal cells. CD320 is a receptor responsible for the uptake of the transcobalamin-bound fraction of vitamin B12 (cobalamin), which is necessary for DNA synthesis, and thus, cell proliferation. CD320 was shown to be overexpressed in many cancers and its potential role as an early cancer biomarker was confirmed in several studies. Consequently, CD320 may represent a promising anti-cancer therapy target. This review summarizes the current advances and perspectives of anti-cancer CD320 targeting therapy, including therapeutic conjugates of vitamin B12, CD320-specific antibodies and nanobodies, nanoparticles loaded with cytotoxic drugs, porphyrin, and the potential of targeted CD320 therapy in attenuation of tumor tissues. Given the growing interest in CD320 as a novel target for anti-cancer therapy, further in vivo studies are required for the investigation of CD320 targeting effects on systemic cytotoxicity.  \nKeywords: CD320; transcobalamin receptor; TCblR; vitamin B12; targeted drug delivery; anti-cancer therapy; selective targeting  \n1. Introduction  \nA successful anti-cancer therapy needs to discriminate between tumor and normal tissue to minimize any adverse effects on the patient [1] . Therefore, targeting the proteins and pathways upregulated in cancer, but not in normal cells, seems to be a viable strategy for therapeutic intervention. Solid tumor cells require a significant amount of nutrients and energy to survive and proliferate, leading to an overexpression of receptors, proteins, and molecules, essential for tumor progression [1] . CD320 is a cell surface receptor that delivers the transcobalamin-bound fraction of vitamin B12 inside the cell [2,3] . It was shown tobe overexpressed in many cancers, including leukemia, lymphoma, breast, ovarian, lung, bone, thyroid, colon, prostate, liver, melanoma, testicular, and brain cancer, thus making ita good target for cancer therapy [1,2,4–8] . This review aims to discuss the perspectives of the CD320 receptor as a potential target for selective anti-cancer therapy.  \n1.1. Vitamin B12 Metabolism  \nVitamin B12 (VB12), also called cobalamin (Cbl), is a water-soluble vitamin. It is a cofactor for two enzymes in humans: methionine synthase (MS) and methylmalonylCoA mutase (MCM) (Figure 1) [9–11] . MS catalyzes the formation of methionine via the methylation of homocysteine involved in methyltransferase reactions, nucleotides,  \nand cysteine synthesis (Figure 1) [11] . MCM converts methylmalonyl-CoA to succinylCoA cr","cbCaip44HGipvnsB","https://ap.wps.com/l/cbCaip44HGipvnsB","pdf",2124977,22,"English","# Abstract\n# Introduction\n## Vitamin B12 Metabolism","[{\"question\":\"Why is targeted therapy important for anticancer treatment?\",\"answer\":\"Most anticancer agents are limited by adverse effects from untargeted cytotoxicity. Targeting cancer-specific proteins and pathways helps discriminate tumor from normal tissue.\"},{\"question\":\"What role does CD320 play in vitamin B12 uptake and cancer cell behavior?\",\"answer\":\"CD320 is responsible for cellular uptake of transcobalamin-bound vitamin B12 (cobalamin). This supports DNA synthesis and cell proliferation, and CD320 is overexpressed in many cancers.\"},{\"question\":\"What therapeutic approaches involving CD320 are summarized in the review?\",\"answer\":\"The review summarizes advances including vitamin B12 therapeutic conjugates, CD320-specific antibodies and nanobodies, nanoparticle systems carrying cytotoxic drugs, and porphyrin-based strategies, as well as prospects for targeted therapy to attenuate tumor tissues.\"}]","CD320 Receptor and Vitamin B12 as Potential Targets for Anti-Cancer Therapy | PDF",1790163077,55,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/56c1f5000597addcb73e725242ad17a8.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8bf90103dbae14887ef965a781b1f547.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/35ebdd09cedafc26e08ea72ae7f6b386.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1dd4325dd8a97a7b45cb6191a4b9c220.webp",980,1385]